Implant Sciences Ships Follow-On Order to Mercury Air Cargo
Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that Mercury Air Cargo , a division of the Mercury Air Group, has placed a follow-on order for the QS-B220™ desktop explosives trace detector (ETD), after having already purchased and deployed the QS-B220 in June. Mercury is deploying its QS-B220 systems at its air cargo screening facility at Los Angeles International Airport, one of the highest volume airports in the world.
"At Mercury Air Cargo, we are honored to work with some of the biggest names in the sky. These companies look to us because of our strong reputation and experience in cargo handling and screening. As such, having an ETD system that provides a low-cost, easy-to-use solution is of the utmost importance," said Darrin Naughton , ICSF Cargo Security Manager at Mercury Air Cargo. "We are pleased to work with Implant Sciences, and have been impressed by their training, service, and support team."
C4ISR Market (Command, Control, Communications, Computers, Intelligence, Surveillance, Reconnaissanc...
"Having a non-radioactive source was another important factor for Mercury and our QS-B220 is the only TSA-qualified ETD that offers this benefit. The ease of use and smaller number of consumables required relative to competing products were other factors that drove the customer's repeat purchase decision," commented Implant Sciences' VP of Sales and Marketing, Darryl Jones . "We look forward to a long-term relationship with Mercury Air Cargo."
Mercury Air Cargo is a TSA Certified Cargo Screening Facility (CCSF) , and as such is required to use TSA qualified systems when screening air cargo packages for explosives before they are loaded onto airplanes.
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company's QS-B220 has also received STAC certification, a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act), and the GSN 2013 Homeland Security Award for "Best Explosives Detection Solution". For further details on the Company and its products, please visit the Company's website at http://www.implantsciences.com .
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our success will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Source : Implant Sciences Corporation
Sep 29 - Oct 1, 2014 - Rome, Italy
Nov 5 - 6, 2014 - Washington, United States